Addressing Important Therapeutic Questions in Squamous NSCLC

Speaker: David Planchard

D. Planchard provides an expert perspective for results and toxicity data in trials performed in advanced squamous NSCLC and reported at ASCO 2015. In particular, he elaborates results of nedaplatin plus docetaxel in advanced or relapsed setting, afatinib vs erlotinib in second-line treatment, and nivolumab vs docetaxel in previously treated advanced or metastatic squamous NSCLC.

Discussion Points

  • Nedaplatin plus docetaxel in advanced or relapsed squamous NSCLC
  • Overall survival analysis from the LUX-Lung 8  study
  • Top line results of CheckMate 017 study